vTv Therapeutics

Small-molecule therapeutics

VTVT · Nasdaq · United States

Share price · VTVT

$16.23-15.25 (-48.44%) 3M

close as of 2026-11-18 · 24h delayed · vol 22K (0.9x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when VTVT's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 18 Nov 2026-6.1%
  2. 16 Nov 2026-10.2%
  3. 1 Oct 2026+3.3%
  4. 14 May 2026+21.4%
  5. 23 Apr 2026-13.8%

    Nothing announced by VTVT that day or the session before.

  6. 16 Mar 2026+14.6%
  7. 10 Feb 2026+11.0%

    Nothing announced by VTVT that day or the session before.

  8. 5 Feb 2026-14.8%

    Nothing announced by VTVT that day or the session before.

  9. 20 Jan 2026-9.8%

    Nothing announced by VTVT that day or the session before.

  10. 9 Jan 2026-13.4%

Share of unusual movement by asset

For each asset, the share of VTVT's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

Assets

(3 total)
3Total Assets
0Approved
2Phase 3 / Filed
1Phase 1–2 / Early
3Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Phase 3
GlucokinaseSmall molecule
Type 1 Diabetes
Phase 3
PDE4Small molecule
Psoriasis
TTP273No recent activity
Phase 2
GLP-1 receptorSmall molecule
Type 2 Diabetes

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
April 2027 (1)
cadisegliatinPhase 3Diabetes Mellitus, Type 1
Est. primary completion 2027-04 · NCT06334133 · CT.gov ↗
What to watch
June 2027 (1)
cadisegliatinPhase 2Type 1 Diabetes (T1D)
Est. primary completion 2027-06 · NCT07616206 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

9 October 2026Topline resultHPP737Prifemilast Phase 3 head-to-head vs apremilast (NCT07712731) met both co-primary endpoints
China · cAMPfield Therapeutics (Newsoara's ex-Greater China licensee) · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$0$7.5M$77M$12M-$10M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$0$8.8M$87M$13M-$11M operating cash flowreport ↗
2026-Q1$37M$9.0M$98M—$9.2M operating cash flowreport ↗
2025-Q3$0$7.0M$99M$8.7M-$5.2M operating cash flowreport ↗
2025-Q2$0$4.1M$26M$6.0M-$5.1M operating cash flowreport ↗
2025-Q1$0$2.8M$31M$5.1M-$5.7M operating cash flowreport ↗
2024-Q3$0$3.2M$42M$4.8M-$6.4M operating cash flowreport ↗
2024-Q2$0$3.4M$46M$5.2M-$6.7M operating cash flowreport ↗
2024-Q1$1.0M$2.6M$52M$4.9M-$7.3M operating cash flowreport ↗
2023-Q3$0$2.8M$8.2M$6.7M-$4.8M operating cash flowreport ↗
2023-Q2$0$4.7M$13M$5.6M-$6.2M operating cash flowreport ↗
2023-Q1$0$3.9M$19M$4.5M-$5.2M operating cash flowreport ↗
2022-Q3$0$3.1M$15M$4.3M-$8.8M operating cash flowreport ↗
2022-Q2<$0.1M$2.2M$18M$3.1M$0.7M operating cash flowreport ↗
2022-Q1$2.0M$3.1M$12M$7.0M-$1.0M operating cash flowreport ↗
2021-Q3$3.0M$2.4M$20M$1.1M-$3.6M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$0$18M$89M$6.7M-$25M operating cash flowreport ↗

vTv Therapeutics reported FY2025 revenue of $0M, down 100% YoY, with R&D spend of $17.86M, up 54.6% YoY. Cash and equivalents were $88.93M at year-end, and the company reported a net loss of $26.97M with a quarterly net burn of $26.97M.

The company expects to complete enrollment in the CATT1 Phase 3 trial of cadisegliatin in the third quarter of 2026 and said its strengthened balance sheet provides funding runway well past the anticipated CATT1 topline readout. In February 2026, it received a $20.0M upfront payment under an amended licensing agreement with Newsoara granting worldwide rights to HPP737, and it also submitted a Phase 2 protocol for cadisegliatin in type 2 diabetes to the Abu Dhabi Department of Health and appointed new Scientific Advisory Board members.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$1.0M$12M$37M$4.6M-$25M operating cash flowreport ↗
2023-FY$0$14M$9.4M$5.1M-$19M operating cash flowreport ↗
2022-FY$2.0M$12M$12M$4.8M-$16M operating cash flowreport ↗
2021-FY$4.0M$13M$13M$3.3M-$19M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-06-26Phillips Anne M. · directorAward / grant (derivative)6,000$35.08$210KForm 4
2026-06-26Al-Marzooqi Fahed · directorAward / grant (derivative)6,000$35.08$210KForm 4
2026-06-26AKKARAJU SRINIVAS · directorAward / grant (derivative)6,000$35.08$210KForm 4
2026-06-26SPIEGELMAN DANIEL K · directorAward / grant (derivative)6,000$35.08$210KForm 4
2026-06-26BAKER BROS. ADVISORS LP; 667, L.P.; Baker Brothers Life Sciences LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC · director; director; director; director; director; directorAward / grant (derivative)6,000——Form 4
2026-06-26BAKER BROS. ADVISORS LP; 667, L.P.; Baker Brothers Life Sciences LP; BAKER FELIX; BAKER JULIAN; Baker Bros. Advisors (GP) LLC · director; director; director; director; director; directorAward / grant (derivative)6,000——Form 4
2026-02-17SEKHRI PAUL J · director, Pres, CEO and Exec ChairpersonAward / grant (derivative)140,000$36.92$5.2MForm 4
2026-02-17Tung Michael Stephen · EVP & CFOAward / grant (derivative)44,969$36.92$1.7MForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 35 reporting institutions held 1.5M shares ($59.0M, 37.8% of shares outstanding).

#InstitutionSharesValue
1SAMSARA BIOCAPITAL, LLC298,496$11.8M
2FMR LLC260,391$10.3M
3MILLENNIUM MANAGEMENT LLC206,288$8.2M
4Siren, L.L.C.163,000$6.5M
5BAKER BROS. ADVISORS LP148,314$5.9M
6Trails Edge Capital Partners, LP139,578$5.5M
7VANGUARD CAPITAL MANAGEMENT LLC108,922$4.3M
8GEODE CAPITAL MANAGEMENT, LLC32,886$1.3M
9NORTHERN TRUST CORP18,052$716K
10VANGUARD FIDUCIARY TRUST CO16,126$640K
11683 Capital Management, LLC16,000$635K
12MARSHALL WACE, LLP13,389$531K
13GOLDMAN SACHS GROUP INC13,350$529K
14BlackRock, Inc.12,602$500K
15STATE STREET CORP10,666$423K